Eris Lifesciences Limited has announced the execution of a corporate guarantee worth INR 75 crores for its wholly owned subsidiary, Eris Bionxt Private Limited (EBPL). The guarantee secures a term loan sanctioned by HDFC Bank, with proceeds earmarked for repaying EBPL's existing loan liabilities.

Corporate Guarantee Details

The company disclosed the guarantee execution under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The formal communication was made to both BSE Limited and National Stock Exchange of India Limited on March 27, 2026.

Transaction Structure and Impact

The corporate guarantee arrangement involves no interest from promoters, promoter groups, or group companies in the transaction. EBPL, being a wholly owned subsidiary, has its financials consolidated with Eris Lifesciences' accounts.

Key Transaction Features:

• Relationship: EBPL is a wholly owned subsidiary of Eris Lifesciences
• Promoter Interest: No promoter or group company involvement
• Financial Treatment: Guarantee appears as contingent liability in standalone financials
• Loan Purpose: Repayment of existing loan liabilities by EBPL

Regulatory Compliance

The disclosure was made in accordance with Regulation 30 requirements and SEBI Master circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Company Secretary and Compliance Officer Milind Talegaonkar signed the regulatory filing, ensuring proper documentation and transparency.

The guarantee details have been uploaded to the company's website as part of standard disclosure practices. This corporate guarantee represents a strategic financial support mechanism for the subsidiary's debt restructuring activities while maintaining consolidated financial reporting standards.

Eris Lifesciences has strategically expanded its metabolic care range by officially launching its generic semaglutide medication branded as 'Sundae' in the Indian pharmaceutical market on 21 March 2026. The diabetes treatment medication represents a significant addition to the company's therapeutic portfolio, offering an affordable alternative for patients requiring semaglutide therapy and targeting nearly 70% of India's diabetes patient population.

Strategic Portfolio Expansion and Regulatory Filing

The company filed a press release under Regulation 30 of SEBI Listing Regulations on 20 March 2026, announcing the official launch date as 21 March 2026. This launch marks Eris Lifesciences' entry into the GLP-1 therapy segment, strengthening its metabolic care offerings. The product specifications and launch details include:

Competitive Pricing Strategy and Product Variants

Eris Lifesciences has positioned Sundae as a breakthrough in diabetes therapy accessibility with competitive pricing across multiple formats. The multi-dose vial variants are priced at ₹1,290 per month for both 2 mg/1.5 ml and 4 mg/3 ml strengths. The company plans to introduce pen-device versions in April with enhanced convenience:

Market Impact and Metabolic Care Focus

The launch represents Eris Lifesciences' strategic expansion into the GLP-1 therapy segment, leveraging its strong presence in diabetology across India while growing its metabolic care range. Semaglutide, a GLP-1 receptor agonist, provides transformative therapy for Type 2 diabetes and weight management through improved glycemic control and weight reduction. The company emphasized that this initiative democratizes access to innovative therapies while addressing India's growing diabetes burden and strengthening its position in the metabolic care market.

Manufacturing and Distribution Network

Sundae is manufactured by Vintus Pharmaceuticals at their Ahmedabad facility and is available across India through Eris Lifesciences' distribution network of approximately 5,000 stockists and 500,000+ retail pharmacies. The multi-dose vial format requires refrigerated storage and offers 42-day stability after first use, providing practical benefits for patients and healthcare providers while supporting the company's expanded metabolic care offerings.